Laboratory for Anti-Geric Testing, Evaluation and Research

抗感冒测试、评估与研究实验室

基本信息

批准号：
9899403
负责人：
RICHARD A MILLER
金额：
$ 78万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-15 至 2019-09-29
项目状态：
已结题

项目摘要

Abstract The NIA Interventions Testing Program represents a multi-site translational research program to evaluate agents hypothesized to extend mouse lifespan by retardation of aging or postponement of late life diseases. Interventions proposed by multiple collaborating scientists from the research community are initially tested, in parallel, at three sites (Jackson Laboratories, Michigan and Texas), using identical, standardized protocols, and using sufficient numbers of genetically heterogeneous mice to provide 80% power for detecting changes in lifespan of 10%, for either sex, after pooling data from any two of the test sites. Forty such lifespan experiments, involving various doses of 25 distinct agents, have been initiated in the first nine years of the ITP. Significant effects on longevity, in one or both sexes, have been documented for 5 of the tested agents: aspirin, NDGA, rapamycin, Acarbose, and 17-α-estradiol. Initial lifespan trials are now underway for 8 agents, as well as comprehensive analyses of the effects of rapamycin, Acarbose, and NDGA on health and on cellular and physiological traits thought likely to mediate the beneficial effects seen. Plans for the next five year period include additional lifespan ("Stage I") trials, detailed analyses ("Stage II") of agents found to increase lifespan, and some increased emphasis on collaborations with other scientists skilled at evaluating traits related to health and disease or at testing ideas about mechanisms of drug action on aging. Each of the three ITP laboratories will bring special expertise to the effort: measures of age-sensitive traits at the Jackson Laboratory, pathology and statistical analysis at Michigan, and pharmacology at the University of Texas.

抽象的 NIA 干预测试计划是一个多地点转化研究计划，旨在评估通过延缓衰老或推迟晚年疾病来延长小鼠寿命的药物被突袭。研究界多位合作科学家提出的干预措施经过初步测试，并行，在三个地点（杰克逊实验室，密歇根州和德克萨斯州），使用相同的标准化协议，并使用足够数量的遗传异质小鼠来提供 80% 的功效来检测汇集任意两个测试站点的数据后，无论性别，寿命均为 10%。 ITP 的前九年已启动了涉及 25 种不同剂量的不同药物的实验。已记录了 5 种测试药物对一种或两种性别的长寿的显着影响：阿司匹林、NDGA、雷帕霉素、阿卡波糖和 17-α-雌二醇目前正在进行 8 种药物的初始寿命试验。以及雷帕霉素、阿卡波糖和 NDGA 对健康和细胞影响的综合分析和生理特征可能会调节未来五年的计划。包括额外的寿命（“第一阶段”）试验，对发现可延长寿命的药物的详细分析（“第二阶段”），一些人更加重视与其他擅长评估相关特征的科学家的合作健康和疾病或测试有关药物对衰老的作用机制的想法。实验室将为这项工作带来特殊的专业知识：杰克逊实验室的年龄敏感特征测量密歇根大学的实验室、病理学和统计分析，德克萨斯大学的药理学。